We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by Kyoto University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00594529
First Posted: January 15, 2008
Last Update Posted: June 23, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Kyoto University
  Purpose
The purpose of this study is to evaluate the safety of liver resection for metastatic, resectable lesions from colorectal cancers after systemic chemotherapy.

Condition Intervention Phase
Colorectal Cancer Liver Metastasis Procedure: Surgery Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Kyoto University:

Primary Outcome Measures:
  • Curative resection rates of liver metastases [ Time Frame: 2 years after the operations ]

Secondary Outcome Measures:
  • Completion rates of neoadjuvant chemotherapy [ Time Frame: 2 years after the operation ]

Estimated Enrollment: 27
Study Start Date: January 2008
Estimated Study Completion Date: May 2013
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Procedure: Surgery
Liver resection for metastatic liver lesions

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically diagnosed as colorectal adenocarcinomas, including cecal, appendiceal, and anal canal cancers.
  2. Liver lesions are measurable by spiral CT or SPIO-MRI scans.
  3. Extrahepatic lesions include lung metastases which can be resected curatively.
  4. Curative resection for metastatic lesions can be performed with residual hepatic functions preserved.
  5. No prior treatment histories for liver lesions, including L-OHP regimens, hepatectomy, hepatic arterial infusion, MCT, or RFA
  6. No evidence of chronic hepatic diseases which affect systemic chemotherapy and/or surgical resection
  7. Performance status (ECOG): 0-1
  8. Vital organ functions, including hematopoietic, cardiac, respiratory and renal functions, are preserved.

Exclusion Criteria:

Excluded are cases with conditions as below:

  1. Peritoneal or pleural fluid retention to be drained.
  2. Multiple malignancies to be treated.
  3. Peripheral neural disturbances.
  4. Active infectious diseases.
  5. Severe watery diarrhea.
  6. Mental disturbances.
  7. Treatment history of continuous, oral or intravenous steroid therapy.
  8. Previous history of ischemic heart diseases.
  9. Coexistent severe diseases including pulmonary fibrosis, interstitial pneumonia, ileus, uncontrollable diabetes, cardiac dysfunction, hepatic failure, or renal failure.
  10. Pregnant.
  11. Previous history of severe drug-induced allergy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00594529


Contacts
Contact: Satoshi Nagayama, Assistant +81-75-751-3227 nagayama@kuhp.kyoto-u.ac.jp

Locations
Japan
Kyoto University Hospital Recruiting
Kyoto, Japan, 606-8507
Contact: Satoshi Nagayama, Assistant    +81-75-751-3227    nagayama@kuhp.kyoto-u.ac.jp   
Sponsors and Collaborators
Kyoto University
  More Information

Responsible Party: Dept. Surgery, Kyoto Univ.
ClinicalTrials.gov Identifier: NCT00594529     History of Changes
Other Study ID Numbers: C-206
UMIN000000961
First Submitted: January 4, 2008
First Posted: January 15, 2008
Last Update Posted: June 23, 2011
Last Verified: August 2009

Keywords provided by Kyoto University:
Neoadjuvant chemotherapy
Metastatic liver lesions from colorectal cancers

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases